Navigation Links
First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder

whom previous treatments had not worked," said Mr. Prokar Dasgupta, consultant urologist at Guy's Hospital, honorary senior lecturer at King's College London, and a co-principal investigator of the study. "These were patients who were seriously affected by their OAB symptoms. At basline, 81 percent of patients in the botulinum toxin type A treatment group and 67 percent in the placebo treatment group were experiencing urge urinary incontinence daily."

OAB is more common than osteoarthritis or diabetes(1,2) and is estimated to affect 16-17% of the population in the U.S. and Western Europe.(3) In addition, the economic burden of OAB is substantial. In the U.S., for example, the total economic cost of OAB has been estimated at $12 billion in 2000 (including costs incurred in the community and institutions).

About the Study

The double-blind trial included 34 patients with OAB and confirmed IDO who had failed on a trial of anticholinergic therapy for six weeks or more due to either poor efficacy or tolerability. They were randomly assigned to treatment with BTX-A 200 U (BOTOX(R)) (16 patients) or placebo (18 patients). The primary outcome measure was change in maximum cystometric capacity (MCC), a measure of urinary bladder capacity. Secondary outcome measures included changes in OAB symptoms, other measures related to urinary bladder filling and pressure, symptoms of urgency and incontinence, and quality of life (QoL). Patients were assessed at 4 and 12 weeks post-injection, at which point the study was unblinded; BTX-A patients were further followed until 24 weeks.

BTX-A treatment significantly increased MCC vs. baseline at 4 weeks (by about 72%) and 12 weeks (by about 45%), compared to a 15 percent decrease in placebo patients at both time points. The differences between MCC changes for the BTX-A and placebo groups were significant at both time points (p<0.0001 and p<0.0011, respectively). Likewise, at 4 and 12 weeks compared to baseline,
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/22/2014)... Sept. 22, 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the ... 26, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. ... New York City . A ... under the investor relations section of Arena,s website at ...
(Date:9/22/2014)... DALLAS , September 22, 2014 ... report "Cell Line Development Market by Product (Equipment, Media ... (Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, ... to 2019", published by MarketsandMarkets, analyzes and studies ... Browse 114 market data tables ...
(Date:9/22/2014)... ANGELES , Sept. 22, 2014 CytRx ... and development company specializing in oncology, today announced that ... key clinical trials of aldoxorubicin, a pivotal global Phase ... and a global Phase 2b clinical trial in small ... Society for Medical Oncology (ESMO) 2014 Congress being held ...
Breaking Medicine Technology:Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6
(Date:9/22/2014)... Starbrite Dental has recently developed a ... Six-Month Smiles is designed to give patients the straighter, ... effective way. , Many people find the idea of ... metal braces for several years, not to mention having ... braces clean, is undesirable and upsetting. , With Dr. ...
(Date:9/22/2014)... September 22, 2014 United States ... of the federal mesh lawsuits ( http://www.meshinjurylawfirm.com/lawsuits/ ) ... been consolidated for pretrial matters, issued an order ... Pelvic Repair System Products Liability Litigation (United States ... Virginia; Case no. 2:12-md-02326)—requiring that four member cases ...
(Date:9/22/2014)... Sundays are when people both exercise more and drink ... intake and physical activity , Findings differ from past ... A new Northwestern Medicine study finds that on days ... -- they drink more alcohol, too. , This is ... daily diary approach for self-reporting physical activity and alcohol ...
(Date:9/22/2014)... Teens and young adults at risk for sexually transmitted ... risky sexual behaviors, according to new recommendations from the ... 20 million new sexually transmitted infections such as gonorrhea ... involve people between 15 and 24 years old, according ... published Sept. 22 in Annals of Internal Medicine ...
(Date:9/22/2014)... Mich. A surprising new study pulls back the ... health care: differences in payment and income between physicians ... don,t. , Contrary to perception, the research indicates, ... favor surgeons and other procedure-performing doctors. , The new ... difference in pay per minute explains why doctors who ...
Breaking Medicine News(10 mins):Health News:Starbrite Dental Introduces Six-Month Smiles 2Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2Health News:We drink more alcohol on gym days 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4
... ... worldwide operator with both CAMTS and EURAMI accreditation and Department of Defense approval, ... Birmingham, AL (PRWEB) ... it has earned full accreditation from the European Aero-Medical Institute (EURAMI). EURAMI is ...
... Nov. 9 HUYA Bioscience International, ... announced a strategic partnership with the School of ... agreement is another in a series of collaborations ... and development institutions to enable and accelerate the ...
... women ages 18 to 68 found that lubricant use during ... ratings of pleasurable and satisfying sex. Personal lubricants ... of sexual intercourse and to reduce the risk of vaginal ... use of lubricants or associated vaginal symptoms. The ...
... The American Public Health Association (APHA) applauds the ... passed last night by the House. , "With passage ... universal coverage, supporting important insurance reforms and moving our ... sick to one that focuses on keeping people healthy," ...
... pain now can take you out of the game later, ... injuries are the talk of the NFL this season, sidelining ... Parker. , Officials at the American Podiatric Medical Association and ... take care of their feet when they play fall sports ...
... ... Through Our Inner Pharmacy" by Dr. Roberto Giraldo shows that AIDS is a result of ... can be either chemical, physical, nutritional and most of all, emotional. , ... Oakland, CA (PRWEB) November 8, 2009 -- ...
Cached Medicine News:Health News:AirMed International, Top U.S. Air Ambulance, Receives EURAMI Accreditation 2Health News:HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 3Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2Health News:Rx for Fall Foot Injuries 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3
Designed for simple operation, the Model 515B pulse oximeter is ideal for use in any clinical setting; from emergency hospital transport to continuous monitoring in Anesthesia, Intensive Care and Gen...
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
... Nellcor NPB-290 and NPB-295 Pulse Oximeters ... provide accuracy, reliability and proven signal ... poorly perfused patients. Equipped with Oxismart ... Technology, these pulse oximeters identify electronic ...
... the revolutionary OxiMax® Pulse Oximetry System, ... Nellcor's best-in-class pulse oximetry with the ... OxiMax N-595 Pulse Oximeter is equipped ... technology, which enables it to withstand ...
Medicine Products: